Drug Trial Radar · NCT05241340
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Feb 15, 2022
Primary completion
Aug 1, 2025
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- The Methodist Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Feb 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-institution, single-arm, phase II clinical trial that tests a novel strategy of neoadjuvant Sasanlimab, an immune checkpoint inhibitor (ICI), in combination with stereotactic body radiation therapy as an in-situ vaccination in patients, who are ineligible to receive cisplatin-based chemotherapy and undergoing radical cystectomy for muscle-invasive bladder cancer.
Conditions
- Urothelial Carcinoma Bladder
Interventions
SasanlimabDrug
Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
Stereotactic Body Radiation TherapyRadiation
This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
Radical Cystectomy + pelvic lymph node dissection + urinary diversionProcedure
This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted. Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite outcome for Feasibility and SafetyTime frame: From date of registration to date of death due to any cause, assessed up to 4 weeks after radical cystectomy
- Clinical benefit rate defined as pathologic complete response (pT0)Time frame: At time of radical cystectomy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Houston Methodist Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.